Objectives Pharmacist-led diabetes collaborative drug therapy management (CDTM) has been shown to improve outcomes. Whether such programmes are effective specifically in Medicaid patients, who face barriers to access and self-management, has not been well characterized. This pilot study explores glycaemic control, utilization and costs associated with pharmacist-led CDTM in a small population of Medicaid patients with type 2 diabetes mellitus (T2DM). Methods A pre-post, historical cohort study was conducted of patients with T2DM and Medicaid coverage who received pharmacist-led CDTM in community-based primary care clinics between 2008 and 2012. Outcomes included change in haemoglobin A1c (HbA1c), healthcare costs and utilization. Results This study included 79 Medicaid patients with T2DM who received pharmacistled CDTM. A subset of 46 patients with Medicaid coverage through an affiliated Medicaid Plan, Healthy U, was identified for additional analysis. At 6-month follow-up, HbA1c was a mean (SD) of 2.0% (2.0) lower than the baseline of 10.3% (1.7). Primary care clinic encounters increased by a mean (median) of 3.4 (2) visits. Per patient health system charges increased by a mean (median) of $4392 ($620), and the amount paid by Medicaid in the Healthy U subset was $822 ($68) higher in the follow-up period. Conclusion A pharmacist-led diabetes CDTM intervention was associated with improved glycaemic control in Medicaid patients, which corresponded with a higher number of primary care visits and observed costs. These findings are consistent with studies not limited to Medicaid, suggesting that CDTM can be effective in type 2 diabetes patients with Medicaid coverage.
Introduction
Pharmacist-led Diabetes Collaborative Drug Therapy Management (CDTM) optimizes drug treatment and has been shown to improve clinical outcomes in primary care settings. [1, 2] CDTM may also have a positive effect on healthcare utilization and costs. [1, 2] Patients with Medicaid coverage are known to face barriers to accessing care and to disease self-management, and therefore may not experience the same CDTM outcomes as a general population. [3, 4] This pilot study evaluated whether a proven primary care-based CDTM intervention is associated with improved glycaemic control in Medicaid patients with type 2 diabetes mellitus (T2DM). It also describes healthcare utilization and costs before and after patients received CDTM.
Methods
A pre-post, historical cohort study was conducted between 1 January 2008 and 31 December 2012 based on electronic medical record (EMR) and administrative data from the University of Utah Healthcare (UUHC) providers, and claims data from an affiliated Medicaid plan, Healthy U. The study setting was the University of Utah Community Clinics (UUCC). During the study period, pharmacists provided CDTM in four UUCC primary care practices with pharmacists working under Collaborative Practice Agreements (CPA) with clinic physicians. CPAs delegate authority to the pharmacist to monitor, prescribe and modify diabetes medication therapy upon referral by the primary care providers. Pharmacists collaborate with the primary care provider to achieve treatment goals, but specific medication management activities are not driven by pre-specified protocols. Thus, the CPAs allow pharmacists to utilize their clinical judgment when making medication changes, including insulin initiation, titration, and dose adjustments for basal, and basal-bolus insulin regimens. PharmD-trained pharmacists provided programme oversight and coordination. All pharmacists delivering the intervention were PharmD or BS trained and successfully completed classroom and real-time clinical education in diabetes management during programme implementation. There were no certified diabetes educators on staff at the time of these analyses.
Referrals were initiated by the primary care provider during a visit or when reviewing patient laboratory results. In addition, pharmacists could request a CDTM referral after interacting with the patient. During CDTM visits, pharmacist provided disease state education and counselling, ordered medication changes and/or dose adjustments as required. Referred patients had an initial face-to-face visit with the pharmacist with regular follow-up visits in person or by phone with content and timing based on patient need. Pharmacist-led CDTM continued for each patient until treatment and/or self-management goals were met, at which time the patient returned to usual drug therapy management by their provider.
The study included adult CDTM patients whose haemoglobin A1c (HbA1c) was ≥7.0% at their first CDTM encounter (index date). Included patients also had a 6-month follow-up HbA1c value and Medicaid coverage at any time during the study period. A subset with Healthy U enrolment for 30+ days was identified to assess utilization and costs per paid claims data.
The primary study outcome was the change in HbA1c from baseline to 6 months follow-up (AE90 days) in the overall study cohort. Attainment of follow-up HbA1c <7.0% was assessed as was HbA1c ≥9.0% in patients with baseline HbA1c ≥9.0%. Exploratory outcomes included costs and utilization pre-and post-index date per UUHC charge data. Cost and utilization data, including health plan costs, were also described in the subset of patients with Healthy U data. CDTM programme costs were not included.
Descriptive statistics were used to present baseline patient characteristics and glycaemic control, cost and utilization data. A paired t-test was used to compare HbA1c between pre-and post-index date periods for the overall cohort. Because economic data are often skewed, costs and utilization were described using both mean and median values.
Results
Of 305 CDTM patients with baseline HbA1c ≥7.0% and a 6-month follow-up HbA1c value, 79 were included in the study. The remaining 226 patients did not have Utah Medicaid coverage during the study period and were not included. Mean (SD) age was 53.2 (12.9) years, and mean baseline HbA1c was 10.3% (1.7) ( Table 1 ). In the Healthy U subset (n = 46), mean age was 52.5 (14.1) years and mean HbA1c was 10.3% (1.6).
Mean reduction in HbA1c from baseline to follow-up in the overall cohort was À2.0% (2.0) (P < 0.001). HbA1c <7.0% was attained by 27.9% of patients. While 69.6% of patients had a baseline HbA1c ≥9.0%, 35.4% had HbA1c ≥9.0% at follow-up.
The mean (median) total costs per UUHC charge data was $4494 ($1553) in the pre-index period and $8887 ($2008) in the post-index date period ( Table 2) . UUCC visits and other outpatient clinic visits increased during the post-index period by a mean (median) of 3.4 (2) and 4.8 (3) visits respectively.
In the Healthy U subset, the mean UUHC total charge was $3557 ($1656) in the pre-index period and $9529 ($1598) in the post-index period. UUCC and other outpatient visits increased by an average of 2.7 (2) and 3. 
Discussion
This study demonstrated that a primary care-based, pharmacistled diabetes CDTM programme designed to optimize diabetes medication use in patients with poorly controlled T2DM is [1, 2, 5] These results are also similar to previous analyses of the overall UUHC CDTM intervention that was not limited by insurance type. A pilot pre-post analysis of N = 111 CDTM patients observed a mean HbA1c reduction of 2.0% from a baseline HbA1c of 10.1% (P < 0.001). [5] A larger comparator study (CDTM n = 303) also identified a 2.0% time-adjusted reduction in HbA1c from a similar baseline of 10.3%. [1] Collaborative drug therapy management patients also experienced an increase in UUCC and outpatient visits, prescription drug use, health system charges, and health plan costs in the post-index period. Given the small sample size however, these results should be interpreted with caution. The small sample size made the study particularly vulnerable to outliers as evident by the notable difference between the observed mean and median costs. Specifically, two patients had inpatient costs that were over four standard deviations greater than the mean. By removing these outliers in the overall cohort analysis, the difference in mean UUHC inpatient charges pre-to post-index was a reduction of $242 versus the observed increase of $2200. Further, the change in mean total costs pre-to post-index date was an increase of $1980 versus the observed increase of $4392.
The findings from this study, in the light of prior analyses, provide preliminary evidence that CDTM worked generally as well in a Medicaid population as in the overall CDTM population in terms of improving glycemic control. This may reflect the nature of the evaluated programme, which allowed the pharmacist to tailor the intervention timing, content and delivery to best suit patient needs. Findings may also be due in part to selection bias as this study was based on Medicaid patients with poorly controlled T2DM and access to primary care who were willing to engage in CDTM.
The study findings are encouraging in suggesting that health systems can design pharmacist-led CDTM programmes that are effective overall and for their Medicaid patients in improving glycemic control. This may be Table 2 Health system charges, health plan costs, and utilization 6-months pre-index and 6-month post-index in medicaid patients with type 2 diabetes receiving collaborative drug therapy management
Category
Total cohort (n = 79) Healthy U subset (n = 46) Medicaid collaborative drug therapy management Eman Biltaji et al.
particularly salient to health systems that have accepted risk for outcomes and costs for some or all of their Medicaid population, although a longer term study in a larger cohort is warranted to better assess cost implications. This pilot study has several limitations in addition to a small size. The cohort was from a limited geographic area that is less diverse than the USA overall. Further, this pilot used patients as their own controls in a pre-post study design. While a pre-post design helps to control for differences between comparison groups, it remains possible that the observed association between CDTM and HbA1c reduction was confounded by other factors such other diabetes management activities and lifestyle changes. Finally, the cost of the CDTM programme was not included in the cost analysis which may underestimate system costs in the postindex date period.
Conclusion
This pilot study showed that pharmacist-led CDTM was associated with improved glycaemic control with higher observed utilization of outpatient services in Medicaid patients with T2DM. Future research will include a larger cohort with a comparison group and examine outcomes over a longer period of time to provide a more robust assessment of pharmacist-led diabetes CDTM in a Medicaid population.
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